Antithrombotic therapy for ischemic stroke: Guidelines translated for the clinician

Journal of Thrombosis and Thrombolysis

Volumn 29, Issue 3, 2010, Pages 368-377

  Krishnan, Anandi ^a   Lopes, Renato D ^a   Alexander, John H ^a   Becker, Richard C ^a   Goldstein, Larry B ^b  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antithrombotic therapy; Guidelines; Ischemic stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPYRIDAMOLE; FIBRINOLYTIC AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; TISSUE PLASMINOGEN ACTIVATOR;

ANTICOAGULATION; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; COMBINATION CHEMOTHERAPY; COMPRESSION GARMENT; DEEP VEIN THROMBOSIS; DRUG INDICATION; EMERGENCY CARE; EVIDENCE BASED MEDICINE; FIBRINOLYTIC THERAPY; HUMAN; INTERMETHOD COMPARISON; INTERMITTENT PNEUMATIC COMPRESSION DEVICE; INTERVENTION STUDY; LOW DRUG DOSE; LUNG EMBOLISM; MONOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SECONDARY PREVENTION; SYMPTOMATOLOGY; THROMBOEMBOLISM; THROMBOSIS PREVENTION; PHYSICIAN; STANDARDS; STROKE;

BRAIN ISCHEMIA; FIBRINOLYTIC AGENTS; HUMANS; PHYSICIANS; PRACTICE GUIDELINES AS TOPIC; STROKE;

EID: 77957938266     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-010-0439-7     Document Type: Review

References (59)

1. Broderick JP (2004) William M. Feinberg Lecture: stroke therapy in the year 2025: burden, breakthroughs, and barriers to progress. Stroke 35:205-211
2. Brown DL, Boden-Albala B, Langa KM et al (2006) Projected costs of ischemic stroke in the United States. Neurology 67:1390-1395
3. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P (2008) Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 133:630S-669S
4. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P (2004) Antithrombotic and thrombolytic therapy for ischemic stroke: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126:483S-512S
5. Akhtar RP, Abid AR, Zafar H, Khan JS (2009) Anticoagulation in patients following prosthetic heart valve replacement. Ann Thorac Cardiovasc Surg 15:10-17
6. Adams RJ, Albers G, Alberts MJ et al (2008) Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke 39:1647-1652
7. Kang C, Schneck M (2004) The role of guidelines in stroke. Semin Cerebrovasc Dis Stroke 4:155-158
8. European Stroke Organisation Executive Committee (2008) Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 25:457-507
9. Guyatt G, Gutterman D, Baumann MH et al (2006) Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians task force. Chest 129:174-181 (Pubitemid 43265259)
10. Panagos PD (2008) The approach to optimizing stroke care. Am J Emerg Med 26:808-816
11. Hart RG, Boop BS, Anderson DC (1995) Oral anticoagulants and intracranial hemorrhage: facts and hypotheses. Stroke 26:1471-1477
12. Lyden P (2008) Thrombolytic therapy for acute stroke-not a moment to lose. N Engl J Med 359:1393-1395
13. Hacke W, Brott T, Caplan L et al (1999) Thrombolysis in acute ischemic stroke: controlled trials and clinical experience. Neurology 53: S3-S14 (Pubitemid 29491978)
14. Marler JR, Tilley BC, Lu M et al (2000) Early stroke treatment associated with better outcome: the NINDS rt-Pa stroke study. Neurology 55:1649-1655
15. Hacke W, Ringleb P, Stingele R (1999) How did the results of ECASS II influence clinical practice of treatment of acute stroke. Rev Neurol 29:638-641
16. Brott T, Bogousslavsky J (2000) Treatment of acute ischemic stroke. N Engl J Med 343:710-722
17. Del Zoppo GJ, Saver JL, Jauch EC et al (2009) Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke 40:2945-2948
18. Chen ZM, Sandercock P, Pan HC et al (2000) Indications for early aspirin use in acute ischemic stroke: a combined analysis of 40 000 randomized patients from the Chinese Acute Stroke Trial and the International Stroke Trial. Stroke 31:1240-1249
19. The International Stroke Trial (1997) A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 349:1569-1581
20. Cerebral Embolism Study Group (1983) Immediate anticoagulation of embolic stroke: a randomized trial. Stroke 14:668-676
21. Cerebral Embolism Study Group (1984) Immediate anticoagulation of embolic stroke: brain hemorrhage and management options. Stroke 15:779-789
22. Hacke W, Kaste M, Bluhmki E et al (2008) Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 359:1317-1329
23. Sandercock PA, Counsell C, Gubitz GJ, Tseng MC et al. (2008) Antiplatelet therapy for acute ischaemic stroke. Cochrane Database Syst Rev CD000029 (3)
24. Sandercock PA, Counsell C, Kamal AK (2008) Anticoagulants for acute ischaemic stroke. Cochrane Database Syst Rev CD000024 (4)
25. Sandercock PA, Counsell C, Tseng MC (2008) Low-molecularweight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke. Cochrane Database Syst Rev CD000119 (3)
26. Haas S (2001) Prevention of venous thromboembolism: recommendations based on the International Consensus and the American College of Chest Physicians Sixth Consensus Conference on Antithrombotic Therapy. Clin Appl Thromb Hemost 7:171-177
27. Kase CS, Pineo GF (2008) Prevention of venous thromboembolism after ischemic stroke. Curr Opin Pulm Med 14:389-396
28. Coull AJ, Lovett JK, Rothwell PM (2004) Population based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education and organisation of services. BMJ 328:326
29. Petty GW, Brown RD Jr, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO (1998) Survival and recurrence after first cerebral infarction: a population-based study in Rochester, Minnesota, 1975 through 1989. Neurology 50:208-216
30. Graham GD (2008) Secondary stroke prevention: from guidelines to clinical practice. J Natl Med Assoc 100:1125-1137
31. Hankey GJ, Warlow CP (2000) Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations. Lancet 355:320-321
32. Bushnell C, Zimmer L, Schwamm L et al (2009) The Adherence eValuation After Ischemic Stroke Longitudinal (AVAIL) Registry: design, rationale, and baseline patient characteristics. Am Heart J 157:428-435
33. Stoeckle-Roberts S, Reeves MJ, Jacobs BS et al (2006) Closing gaps between evidence-based stroke care guidelines and practices with a collaborative quality improvement project. Jt Comm J Qual Patient Saf 32:517-527
34. Schwamm LH, Fonarow GC, Reeves MJ et al (2009) Get with the Guidelines-Stroke is associated with sustained improvement in care for patients hospitalized with acute stroke or transient ischemic attack. Circulation 119:107-115
35. LaBresh KA, Reeves MJ, Frankel MR, Albright D, Schwamm L (2008) Hospital treatment of patients with ischemic stroke or transient ischemic attack using the "Get with the Guidelines" program. Arch Intern Med 168:411-417
36. Grotta JC (1999) Acute stroke therapy at the millennium: consummating the marriage between the laboratory and bedside. The Feinberg lecture. Stroke 30:1722-1728
37. Liebeskind DS (2009) Reversing stroke in the 2010s: lessons from Desmoteplase in Acute Ischemic Stroke-2 (DIAS-2). Stroke 40:315-318
38. Johnston SC (2008) The 2008 William M. Feinberg lecture: prioritizing stroke research. Stroke 39:3431-3436
39. Turley KR, Toledo-Pereyra LH, Kothari RU (2005) Molecular mechanisms in the pathogenesis and treatment of acute ischemic stroke. J Invest Surg 18:207-218
40. Adkins DL, Schallert T, Goldstein LB (2009) Poststroke treatment: lost in translation. Stroke 40:8-9
41. Wardlaw JM (2001) Overview of Cochrane thrombolysis metaanalysis. Neurology 57: S69-S76
42. Ingall TJ (2009) Intravenous thrombolysis for acute ischemic stroke: time is prime. Stroke 40:2264-2265
43. Aronowski J, Ostrow P, Samways E, Strong R, Zivin JA, Grotta JC (1994) Graded bioassay for demonstration of brain rescue from experimental acute ischemia in rats. Stroke 25:2235-2240
44. Aronowski J, Strong R, Grotta JC (1997) Reperfusion injury: demonstration of brain damage produced by reperfusion after transient focal ischemia in rats. J Cereb Blood Flow Metab 17:1048-1056
45. Hacke W, Furlan AJ, Al-Rawi Y et al (2009) Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebocontrolled study. Lancet Neurol 8:141-150
46. Study of the combination therapy of Rt-Pa and eptifibatide to treat acute ischemic stroke (CLEAR-ER Stroke Trial). Clinical Trials.gov Identifier NCT00894803. Available at http://www.clinical trials.gov/ct2/show/NCT00894803? term=NCT00894803&rank=1. Accessed 4 December 2009
47. Adjunctive drug treatment for ischemic stroke patients. Clinical Trials.gov Identifier NCT00061373. Available at http://www.clinicaltrials.gov/ ct2/show/NCT00061373?term=nct00061373 &rank=1. Accessed 4 December 2009
48. Enoxaparin and/or minocycline in acute stroke. Clinical Trials.gov Identifier NCT00836355. Available at http://www.clinical trials.gov/ct2/show/ NCT00836355?term=nct00836355&rank=1. Accessed 4 December 2009
49. Lohrmann J, Becker RC (2008) New anticoagulants-the path from discovery to clinical practice. N Engl J Med 358:2827-2829
50. Harrington RA (2003) Developing drugs to prevent and treat arterial thrombosis. Available at http://www.cardiologyrounds.org/crus/cardious-0809.pdf. Accessed 4 December 2009
51. Coull BM, Williams LS, Goldstein LB et al (2002) Anticoagulants and antiplatelet agents in acute ischemic stroke: report of the Joint Stroke Guideline Development Committee of the American Academy of Neurology and the American Stroke Association (a division of the American Heart Association). Neurology 59:13-22
52. Becker RC, Rusconi C, Sullenger B (2005) Nucleic acid aptamers in therapeutic anticoagulation. Technology, development and clinical application. Thromb Haemost 93:1014-1020
53. Becker RC, Oney S, Becker KC, Rusconi CP, Sullenger B (2007) Nucleic acid aptamers and their complimentary antidotes. Entering an era of antithrombotic pharmacobiologic therapy. Hamostaseologie 27:378-382
54. Becker RC (2007) Emerging paradigms, platforms, and unifying themes in biomarker science. J Am Coll Cardiol 50:1777-1780
55. Rusconi CP, Roberts JD, Pitoc GA et al (2004) Antidote-mediated control of an anticoagulant aptamer in vivo. Nat Biotechnol 22:1423-1428
56. Rusconi CP, Scardino E, Layzer J et al (2002) RNA aptamers as reversible antagonists of coagulation factor Ixa. Nature 419:90-94
57. Oney S, Nimjee SM, Layzer J et al (2007) Antidote-controlled platelet inhibition targeting von Willebrand factor with aptamers. Oligonucleotides 17:265-274
58. Chan MY, Cohen MG, Dyke CK et al (2008) Phase 1b randomized study of antidote-controlled modulation of factor Ixa activity in patients with stable coronary artery disease. Circulation 117:2865-2874
59. Chan MY, Rusconi CP, Alexander JH, Tonkens RM, Harrington RA, Becker RC (2008) A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor Ixa inhibitor. J Thromb Haemost 6:789-796